Moderna stock drops as Goldman Sachs cuts rating
Moderna (NASDAQ:MRNA) shares about 3% ahead of Wednesday market open after Goldman Sachs cut its rating on the stock to Neutral from Buy.
CRISPR Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...
Triple Combination Therapy Market to Surge to US$ 29.2 Billion by 2034, Growing at a 6.5% CAGR | Fact.MR Report
Adoption of Triple Combination Therapy Accelerates at Unprecedented Rates as Precision Medicine Revolution ContinuesRockville, MD, Jan. 29, 2025 (GLOBE NEWSWIRE) -- According to Fact.MR, a market ...
A long-awaited alternative to opioids is on the FDA doorstep. Can Vertex seal the deal?
Vertex Pharmaceuticals’ non-opioid pain medication is up for FDA approval this week. Other drugmakers have found safer ...